About / Ronald R

Ronald R covers the GLP-1 and metabolic-medicine beat: what these drugs are approved for, what the trials actually measured, what the labels say, what they cost, and how supply and policy keep moving underneath all of it.

He works from primary documents — prescribing information, trial registries, regulatory notices, company statements — and dates every figure, because a price or a shortage that was true last quarter frequently is not.

He does not give medical advice, and does not tell readers what to take.

Written by Ronald R

• Orforglipron vs Tirzepatide: A Daily Pill Against a Weekly Injection

  2026-09-06

• Survodutide vs Tirzepatide: Reading a Brand-New Phase 3 Against an Approved Drug

  2026-09-06

• Tirzepatide vs Semaglutide: The One Trial That Compared Them Directly

  2026-09-06

• GLP-1 Pills in 2026: What the Two Approved Tablets Cost, and What They Do

  2026-09-06

• What the GLP-1 Brain Research Actually Found

  2026-09-05

• Compounded Tirzepatide vs Zepbound: What Changed When the Shortage Ended

  2026-09-05

• Retatrutide vs Tirzepatide: What the Trials Show, and What Is Not Known Yet

  2026-09-05

• How Much Do GLP-1 Medicines Cost in 2026? Every Price, Dated

  2026-09-05

• Retatrutide: Approval Status, Trial Doses, Results and What Is Being Sold Under Its Name

  2026-09-05

glp1ledger is operated by Sherdas LLC. How this site works.